GlobeNewswire

Elastic Releases 6.0 with New User Experience Features for Managing and Operating the Elastic Stack

Dela

Elastic achieves 150 million product downloads

MOUNTAIN VIEW, Calif. and AMSTERDAM, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Elastic, the company behind Elasticsearch, and the Elastic Stack, the most widely-used collection of open source products (with more than 150 million downloads since 2012) for solving mission-critical use cases like search, logging, security, metrics, and analytics, today announced general availability of its 6.0 release. Available both for Elastic's on-premise offerings and in Elastic Cloud, the 6.0 release includes new capabilities to help organizations manage, deploy, and operate the Elastic Stack, new Kibana accessibility features, and performance improvements for handling data to improve storage and reduce costs.

"I would like to thank our entire user community and customers for always pushing us to make our products better and contributing to our releases," said Shay Banon, Elastic Founder & CEO. "The 6.0 release takes our entire stack to another level with lots of new user experience features for visualizing data, managing the operations for their Elastic Stack deployments, upgrading between versions, and ingesting data from new data sources."

Elasticsearch

  • Simplified upgrade experience to migrate between major versions
  • New operation-based data replication framework, for faster data recovery
  • New way to store sparse fields efficiently, lowering storage costs
  • Index time sorting for faster sorted query performance
  • Distributed watch execution for better control and performance at scale (X-Pack)
  • New security defaults for an tighter security-by-default stance (X-Pack)

Kibana

  • Full screen mode for dashboards; leave no pixel behind
  • Accessibility improvements such as color contrast, support for screen readers, and keyboard navigation
  • Kuery, a new query language that takes the Kibana search bar experience up a notch
  • Single click export of Kibana search results to CSV files (Free in X-Pack Basic)
  • Upgrade Assistant UI, to simplify your migration experience (Free in X-Pack Basic)
  • Dashboard Only mode, for worry free dashboard sharing (X-Pack)
  • New Alerting UI for easy creation and management of threshold-based alerts (X-Pack)
  • Automatic email notifications on Elastic Stack monitoring alerts (X-Pack)

Beats

  • Auditbeat, a new Beat for ingesting complex from Linux Audit Framework
  • Improved monitoring for Docker and Kubernetes deployments
  • Metricbeat modules: RabbitMQ, Aerospike, Memcached, Dropwizard, vSphere
  • Filebeat modules: Redis, ICINGA

Logstash

  • Migration tool to easily convert Ingest Node pipelines into Logstash configs
  • Run and manage multiple Logstash pipelines
  • Pipeline Viewer, a better way to view and monitor your Logstash pipelines (Free in X-Pack Basic)
  • New Central Management UI to create and manage multiple Logstash pipelines in a single place (X-Pack)

Elastic Cloud Enterprise

  • Elastic Cloud Enterprise (ECE) 1.1: support for 6.0, offline installation, and new features for simplifying provisioning, management and monitoring

Learn More

About Elastic
Elastic builds software to make data usable in real time and at scale for search, logging, security, and analytics use cases. Founded in 2012, the company develops the open source Elastic Stack (Elasticsearch, Kibana, Beats, and Logstash), X-Pack (commercial features), and Elastic Cloud (a hosted offering). To date, there have been more than 150 million cumulative downloads. Backed by Benchmark Capital, Index Ventures, and NEA with more than $100 million in funding, Elastic has a distributed workforce with more than 600 employees in 30 countries. Learn more at elastic.co

Elastic Media Contacts:

AMER
Michael Lindenberger
Reidy Communications for Elastic
michael@reidycommunications.com

APAC
Jeff Yoshimura
Communications @ Elastic
pr@elastic.co




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elastic via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum